Dignitana AB: Chronos Trade Medical joins Dignitana as exclusive distributor in Romania

Dignitana has signed a Distribution Agreement for Chronos Trade Medical to be the exclusive provider of The DigniCap Scalp Cooling System in Romania. DigniCap is an innovative medical device clinically proven to minimize hair loss from chemotherapy.

Chronos has purchased two DigniCap Delta systems to initiate sales in the Romania and will attend Distributor Training at the Dignitana office in Lund.

"With breast cancer as the leading cancer among women in Romania, there is strong demand to address the side effect of hair loss from chemotherapy. I am pleased that we can address this need by partnering with Dignitana to bring this leading technology to our cancer centers," said Razvan Mihai Calin, CEO of Chronos Trade Medical.

"Increasing availability of DigniCap to more patients is top priority for Dignitana and it is clear that Chronos shares this objective. With extensive experience in the market, Chronos has all the right resources to deliver strong growth in the region," said Fredrik Jonsson, Dignitana CEO.

In recent years high-quality cancer care has become a greater priority in Romania. Introduced in 2023, Romania's National Plan for Beating Cancer is focused on ensuring an integrated, multidisciplinary approach to cancer care as well as providing health innovation, cutting edge therapies, support and palliative services for cancer patients - making a strong case for patient access to DigniCap. In 2020, breast cancer accounted for 26.8 percent of all female cancer diagnoses in Romania with about 12,700 new cases diagnosed each year (Globocan).

The FDA-cleared DigniCap Delta device uses industry-leading thermoelectric cooling to minimize hair loss that is a side effect of chemotherapy prescribed to treat solid tumors such as those from breast cancer, ovarian cancer and prostate cancer. Recognized internationally as a standard of care and quality of life advancement for cancer patients, scalp cooling is a treatment recommendation in the clinical practice guidelines published by National Comprehensive Cancer Network® (NCCN), European Society for Medical Oncology (ESMO), and Cancer Australia. It is available in cancer centers around the globe.